| Stage | GLIBA | % of rev | CMCSA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $261M | 100.00% | $29.3B | 100.00% | CMCSA ×112.25 |
| Gross profit | $261M | 100.00% | $21.8B | 74.35% | GLIBA +25.7pp |
| Operating income | $29M | 11.11% | $5.3B | 18.16% | CMCSA +7.0pp |
| Pre-tax income | $23M | 8.81% | $4.4B | 15.18% | CMCSA +6.4pp |
| Net income | $16M | 6.13% | $3.4B | 11.48% | CMCSA +5.3pp |
| Stage | GLIBA | CMCSA | Gap · A − B |
|---|---|---|---|
| Revenue | $261M100.00% | $29.3B100.00% | CMCSA ×112.25 |
| Gross profit | 100.00%$261M | 74.35%$21.8B | GLIBA +25.7pp |
| Operating income | 11.11%$29M | 18.16%$5.3B | CMCSA +7.0pp |
| Pre-tax income | 8.81%$23M | 15.18%$4.4B | CMCSA +6.4pp |
| Net income |
| 6.13%$16M |
| 11.48%$3.4B |
| CMCSA +5.3pp |
None
No disclosed counterparties: GLIBA.